Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups

Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?

“…112 Further analysis showed the effects of vardenafil were similar in the organic, psychogenic and mixed groups, and regardless of baseline severity. 113,114 Similar results were obtained in a 6 month trials of 5, 10 or 20 mg vardenafil or placebo in 805 ED patients, mostly of organic aetiology, 115 a 6 month trial of 5, 10 or 20 mg vardenafil in 1650 men in a broad of men with ED, 116 and in flexible-dose studies starting with 10 mg vardenafil. 117,118 A 12-month extension to a 12-month trial of 566 men with ED of 10 and 20 mg vardenafil, showed that vardenafil had long-term efficacy, reliability and tolerability.…”

“…One point of difference is that no alterations of colour vision were reported in the early studies with vardenafil. 112,113,116,117 whereas transient visual disturbances were reported in the early studies with sildenafil. There are no clinical trials directly comparing sildenafil and vardenafil, and such trials should be undertaken to determine if there are any differences between the drugs.…”

Efficacy and Tolerability of Vardenafil in Men With Mild Depression and Erectile Dysfunction: The Depression-Related Improvement With Vardenafil for Erectile Response Study

“…Vardenafil is a potent selective PDE-5 inhibitor that has been shown to be highly efficacious in men with erectile dysfunction, irrespective of severity or disease classification (organic, psychogenic, or mixed) (11) or underlying etiology (12). The drug is well tolerated and is associated with a rapid and reliable treatment response.…”

Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports

“…17 A total of 10 trials involving 6809 men met all the eligibility criteria and were included in this systematic review (Table 1). [18][19][20][21][22][23][24][25][26][27] Five trials were published in peer-reviewed journals, [18][19][20][21][22] but one of them was a reanalysis of a previous trial 18 focusing on patient subgroups. 22 One trial was submitted by the sponsor (Bayer AG) to the FDA for approval of the drug.…”

“…27 Four trials were presented in conference meetings and were published as abstracts. [23][24][25][26] Eight reported that they were randomized, double blind and placebo-controlled, [18][19][20][21][22][23][24][25]27 and one was reported only as randomized and placebo-controlled. 26 However, only two trials described the generation of allocation sequences.…”